Markets:

Overview

News

Currencies

International

Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

56.90 -0.79 (-1.37%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Nasdaq Tumbles 2%; Timber Pharmaceuticals Shares Spike Higher ↗

February 24, 2023

U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 450 points on Friday. The Dow traded down 1.39% to 32,692.94 while the NASDAQ fell 2.14% to 11,342.36. The S&P 500 also...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023 ↗

February 24, 2023

Via Benzinga

US Stocks Open Lower; Dow Drops 1% ↗

February 24, 2023

U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Friday. Following the market opening Friday, the Dow traded down 1.05% to 32,807.33 while the NASDAQ fell 1.52% to...

Via Benzinga

Expert Ratings for Nektar Therapeutics ↗

May 31, 2022

Within the last quarter, Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings:

Via Benzinga

After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring ↗

April 26, 2022

Via Benzinga

PIXY Stock Alert: What to Know as ShiftPixy Utilizes ChatGPT for Recruiting ↗

February 24, 2023

ShiftPixy (PIXY) stock is on the move Friday after the company announced plans to use ChatGPT for recruiting and hiring.

Via InvestorPlace

BA Stock Alert: Boeing Halts Deliveries of 787 Dreamliners ↗

February 24, 2023

Boeing (BA) stock is a hot topic among traders on Friday after the aerospace company halted deliveries of its 787 Dreamliner.

Via InvestorPlace

Why Is Nektar Therapeutics (NKTR) Stock Down 39% Today? ↗

February 24, 2023

Nektar Therapeutics (NKTR) stock is taking a beating on Friday following the release of poor Phase 2 clinical trial data.

Via InvestorPlace

Why Nektar Therapeutics Stock Is Plunging Today ↗

February 24, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 24, 2023

Via Benzinga

Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗

February 24, 2023

Gainers Cingulate Inc (NASDAQ: CING) rose 85.7% to $2.08 in pre-market trading after the company disclosed top-line results from Fed/Fast study of lead asset CTx-1301 for ADHD.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

February 24, 2023

It's time to start off trading on Friday with a breakdown of the biggest pre-market stock movers worth keeping an eye on!

Via InvestorPlace

US Stocks Stare At More Losses In a Lackluster Week: Can Inflation Data Salvage Year's Rally? ↗

February 24, 2023

See-sawing sentiment continues to persist on Wall Street, as index futures signal weakness on Friday after Thursday's positive close. A key inflation reading due ahead of the market opening may largely...

Via Benzinga

BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

February 24, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Glancy Prongay & Murray LLP Announces Investigation of Nektar Therapeutics (NKTR)

February 01, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 29, 2022

Via Benzinga

Analyst Says IO Biotech's Cancer Treatment Approach 'Differentiated' ↗

November 21, 2022

Via Benzinga

Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus ↗

November 14, 2022

The major U.S. index futures are pointing to a moderately lower opening on Wall Street on Monday, as optimism following a tamer inflation data gives way to apprehension. The yield on the benchmark...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

December 23, 2022

OnFriday, 143 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

November 30, 2022

During Wednesday's session, 107 stocks hit new 52-week lows.

Via Benzinga

PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics ↗

October 07, 2022

Via Benzinga

Nektar Therapeutics's Return On Capital Employed Insights ↗

August 23, 2022

Nektar Therapeutics (NASDAQ:NKTR) brought in sales totaling $21.59 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 75.97%, resulting in a loss of $159.07...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022 ↗

August 08, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 05, 2022

Via Benzinga

Recap: Nektar Therapeutics Q2 Earnings ↗

August 04, 2022

Nektar Therapeutics (NASDAQ:NKTR) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact ↗

July 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Nektar Therapeutics's Return On Capital Employed Insights ↗

May 31, 2022

According to Benzinga Pro data, during Q1, Nektar Therapeutics (NASDAQ:NKTR) posted sales of $24.82 million. Earnings were up 37.94%, but Nektar Therapeutics still reported an overall loss of $90.39...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 05, 2022

Gainers

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

The Daily Biotech Pulse - Tuesday, April,26 ↗

April 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Nektar Therapeutics - Common Stock (NQ:NKTR)

All News about Nektar Therapeutics - Common Stock

Starting at $3.75/week.

Subscribe Today